New York, NY, United States of America

Yupu Qiao

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Intra-Cellular Therapies, Inc.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yupu Qiao: Innovator in Organic Compounds

Introduction

Yupu Qiao is a notable inventor based in New York, NY (US). He has made significant contributions to the field of organic compounds, particularly in the development of prodrugs and analogs that have potential therapeutic applications.

Latest Patents

Yupu Qiao holds 1 patent related to organic compounds. His invention pertains to specific prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one. This patent includes pharmaceutical compositions and methods of use as sedatives, hypnotics, anxiolytics, and anesthetics. It also addresses treatment methods for depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, along with combinations with other agents.

Career Highlights

Yupu Qiao is currently associated with Intra-Cellular Therapies, Inc., where he continues to advance his research and innovations in the pharmaceutical field. His work is pivotal in developing new therapeutic options for various mental health conditions.

Collaborations

Yupu collaborates with talented professionals in his field, including Kimberly Vanover and Peng Li. Their combined expertise contributes to the innovative environment at Intra-Cellular Therapies, Inc.

Conclusion

Yupu Qiao's contributions to organic compounds and his innovative patent highlight his role as a significant inventor in the pharmaceutical industry. His work has the potential to impact the treatment of various central nervous system disorders.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…